Ritu Salani, MD

Ritu Salani, MD, MBA, is a board-certified gynecologic oncologist who is a nationally renowned expert in the treatment of gynecologic malignancies with over 15 years of experience. She serves as the Director of Gynecologic Oncology at UCLA.

Articles

Looking Ahead: The Evolving Role of ADCs in Gynecologic Malignancies

June 20th 2025

Panelists discuss how the evolving role of antibody-drug conjugates (ADCs) in treating gynecologic cancers, including ovarian, endometrial, and cervical cancers, offers exciting opportunities for more personalized treatments that could improve progression-free survival and quality of life, while addressing challenges in therapy sequencing, toxicity management, and biomarker-driven approaches.

Mirvetuximab Soravtansine in Practice: Expert Approaches to Adverse Event Management in Ovarian Cancer

June 20th 2025

Panelists discuss how early detection and proactive management of ocular toxicities associated with mirvetuximab soravtansine, including regular screening, eye exams, and collaboration with ophthalmologists, are essential for ensuring timely intervention and minimizing long-term complications such as cataracts, particularly as the drug transitions to broader clinical use.

Navigating T-DXd-Related Toxicity: Mitigation and Management Strategies in Gynecological Cancer

June 20th 2025

Panelists discuss how managing interstitial lung disease (ILD) associated with antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine requires proactive monitoring, including baseline and ongoing chest CT scans, early intervention with steroids, and close collaboration with pulmonologists and radiologists to minimize risks and ensure patient safety during treatment.

Exploring Emerging ADCs and Their Potential Impact in Gynecologic Cancers

June 13th 2025

Panelists discuss how the rapid evolution of antibody-drug conjugates (ADCs) in gynecologic cancers, including promising agents such as mirvetuximab soravtansine and toriluzumab, is generating excitement, with a focus on optimizing treatment sequencing and exploring combinations of ADCs to improve outcomes for patients with platinum-resistant ovarian cancer.

Navigating Treatment Sequencing Decisions in the Ovarian Cancer Paradigm

June 13th 2025

Panelists discuss how mirvetuximab soravtansine (MIRV), an antibody-drug conjugate, has become a vital treatment for platinum-resistant ovarian cancer, highlighting its effectiveness in patients with high folate receptor alpha expression, its well-tolerated profile with manageable toxicities, and the potential for expanding its use into earlier treatment lines and combination therapies.

Efficacy, Tolerability, and Quality of Life with ADCs in Gynecological Malignancies

June 6th 2025

Panelists discuss how the accelerated approval of trastuzumab deruxtecan (T-DXd) offers a promising new treatment option for patients with HER2-positive gynecologic cancers, while highlighting the need for confirmatory trials to refine patient selection, testing methodologies, and treatment sequencing strategies, as well as managing varying patient responses and addressing tolerability concerns.

Integrating T-DXd in HER2+  Gynecologic Cancers: Impact on Treatment Decisions and Sequencing

June 6th 2025

Panelists discuss how the recent accelerated approval of trastuzumab deruxtecan (T-DXd) in HER2-expressing endometrial cancer prompts critical questions about treatment sequencing, as clinicians weigh efficacy, toxicity, and emerging evidence to personalize therapy in a rapidly evolving gynecologic oncology landscape.

Expert Perspectives: Standardizing HER2 Testing in Gynecological Cancer

May 30th 2025

Panelists discuss how evolving insights into HER2 expression—drawn from parallels with breast cancer—highlight the need for standardized HER2 testing in gynecologic oncology, as emerging data on HER2-low status and variability in current testing approaches underscore both the therapeutic potential of antibody-drug conjugates (ADCs) and the challenges of implementing precision medicine in this setting.

Molecular Testing in Ovarian and Endometrial Cancer: Evolving Approaches and Best Practices

May 30th 2025

Panelists discuss how antibody-drug conjugates (ADCs) and molecular testing are reshaping treatment strategies in ovarian and endometrial cancers by enabling more personalized, targeted care, while addressing practical challenges such as tissue limitations, tumor heterogeneity, and the evolving role of liquid biopsy in optimizing diagnostic accuracy.

Dr Salani on Novel Trial Designs and Therapies in Gynecologic Malignancies

March 11th 2025

Ritu Salani, MD, MBA, discusses considerations in clinical trial design and the evolving role of HER2-targeted ADCs in gynecologic malignancies.

Dr Salani on Managing Mirvetuximab Soravtansine–Associated Ocular Toxicities in Ovarian Cancer

December 17th 2024

Ritu Salani, MD, MBA, discusses the management of ocular toxicities associated with mirvetuximab soravtansine in ovarian cancer.

Dr Salani on Research With MEK Inhibition in KRAS-Mutant Serous Ovarian Cancer

May 20th 2024

Ritu Salani, MD, MBA, discusses pathways implicated in low-grade serous ovarian cancer that may be viable for targeted therapy development.

Future Perspectives on HER2 ADCs in Gynecological Cancer

February 8th 2024

Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.

Expert Insights on HER2 Testing in Gynecological Cancers

February 8th 2024

Ritu Salani, MD, provides expert insights regarding HER2 testing in patients with gynecological cancers, emphasizing the need for standardization in testing practices and greater clarity surrounding the incidence of HER2 positivity across gynecological cancers.

HER2 ADCs in Cervical Cancer: A Promising Therapeutic Frontier

February 1st 2024

Ritu Salani, MD, highlights impactful findings from the DESTINY-PanTumor02 study in patients with cervical cancer, highlighting the promising role of HER2-directed ADCS in this treatment space.

HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape

February 1st 2024

Ritu Salani, MD, discusses impactful efficacy signals from T-DXd in the DESTINY-PanTumor02 study for endometrial cancer, marking a potential breakthrough in this treatment field.

Dr Salani on the De-Escalation of Therapy in Gynecologic Oncology

January 29th 2024

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

Emerging Data for HER2 ADCs in Ovarian Cancer

January 25th 2024

Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.

Landscape Surrounding HER2 ADCs in GI Cancers

January 25th 2024

Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.

Targeting HER2 Alterations with ADCs in NSCLC

January 18th 2024

Martin Dietrich, MD, PhD, examines the safety and efficacy of HER2-directed ADCs in NSCLC, emphasizing significant differences in response associated with HER alterations.

x